Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions
Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, today announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset licensing within the country. The establishment of this subsidiary marks an important milestone for Curative Biotech as it expands its reach and presence in the Japanese market. The new entity has been named Curative Biotech Japan K.K. (“Curative Japan”) and will be located at 2-23-12 Shimomeguro Meguro ku, Tokyo 153-0064 Japan.
- The establishment of this subsidiary marks an important milestone for Curative Biotech as it expands its reach and presence in the Japanese market.
- The Japanese subsidiary, once operational, will select a seasoned pharmaceutical and business executive, who will assume the role of Representative Director.
- "We are excited to establish our presence in Japan through the creation of our subsidiary," said Paul Michaels, Co-CEO of Curative Biotech.
- The establishment of the Japanese subsidiary represents a significant step forward in the mission.”